dexamethasone

4mg/mL injection, 1mg/mL oral mixture*

© Department for Health and Ageing, Government of South Australia. All rights reserved.

Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Dose and Indications

Facilitating extubation in ventilated babies with evolving or established chronic lung disease

Intravenous, Oral

Initial dose: 0.05 to 0.075mg/kg/dose twice a day, then review response and wean every 2 to 3 days

Dose and duration of treatment are dependent on clinical response and directed by a neonatologist. The DART trial protocol is an example of dexamethasone weaning which may be considered (Doyle LW et al, 2006).

Treatment of post-intubation laryngeal oedema

Intravenous, Oral

0.075mg/kg/dose given 12 hourly for up to three doses

Preferably started 12 hours (at least 4 hours) prior to tube removal.
Preparation and Administration

Intravenous for doses less than 0.4mg
Dilute 1mL of the 4mg/mL dexamethasone sodium phosphate injection with 7mL sodium chloride 0.9% (to a total volume of 8mL). The resulting solution contains 0.5mg/mL dexamethasone.

<table>
<thead>
<tr>
<th>Dose</th>
<th>0.05mg</th>
<th>0.1mg</th>
<th>0.15mg</th>
<th>0.2mg</th>
<th>0.25mg</th>
<th>0.3mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.1mL</td>
<td>0.2mL</td>
<td>0.3mL</td>
<td>0.4mL</td>
<td>0.5mL</td>
<td>0.6mL</td>
</tr>
</tbody>
</table>

To be administered as a slow push over at least 3 minutes
Discard any remaining solution.

Intravenous for doses greater than 0.4mg
Use undiluted dexamethasone sodium phosphate injection (4mg/mL).

<table>
<thead>
<tr>
<th>Dose</th>
<th>0.4mg</th>
<th>0.8mg</th>
<th>1.2mg</th>
<th>1.6mg</th>
<th>2mg</th>
<th>2.4mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.1mL</td>
<td>0.2mL</td>
<td>0.3mL</td>
<td>0.4mL</td>
<td>0.5mL</td>
<td>0.6mL</td>
</tr>
</tbody>
</table>

To be administered as a slow push over at least 3 minutes.
Discard any remaining solution.

Oral
Oral dexamethasone solution contains 1mg/mL of dexamethasone.

*Oral dexamethasone doses only require dilution when doses smaller than or equal to 0.1mg are administered, to ensure accuracy of dose.*

Dilution to 0.1mg/mL
Dilute 0.5mL of dexamethasone oral solution (1mg/mL) with 4.5mL of water for irrigation (to a total volume of 5mL). The resulting solution contains 0.1mg/mL.

<table>
<thead>
<tr>
<th>Dose</th>
<th>0.04mg</th>
<th>0.06mg</th>
<th>0.08mg</th>
<th>0.1mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.4mL</td>
<td>0.6mL</td>
<td>0.8mL</td>
<td>1mL</td>
</tr>
</tbody>
</table>

Give with or after feeds to minimise gastrointestinal irritation.
Discard remaining diluted solution.

Compatible Fluids
Glucose 5%, sodium chloride 0.9%, glucose 10%, glucose/sodium chloride combinations
dexamethasone
4mg/mL injection, 1mg/mL oral mixture*

Adverse Effects

Common
Adrenal suppression, increased susceptibility to infection, masking of signs of infection, sodium and water retention, hypertension, hypokalaemia, hyperglycaemia, osteoporosis, fractures, delayed wound healing, skin atrophy, bruising, hirsutism, growth retardation, myopathy, muscle wasting, cushingoid appearance, weight gain, cataracts, gastritis

Monitoring
> Monitor for hypertension, hyperglycaemia and sepsis as per local unit protocol.

Practice Points
> *Oral mixture is prepared at Women’s & Children’s Health Network Pharmacy. If not available the injection solution may be given orally (please note that these solutions are different concentrations).
> Caution with use in the following patient groups: gastric ulceration, hypertension, concurrent use of indomethacin/ibuprofen, renal impairment or cardiac disease.
> If an infant has been on dexamethasone in the last month, cover for possible adrenal suppression during subsequent episodes of stress with IV hydrocortisone.

<table>
<thead>
<tr>
<th>Steroid equivalents (glucocorticoid activity of oral or intravenous dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortisone Acetate</td>
</tr>
<tr>
<td>Dexamethasone</td>
</tr>
<tr>
<td>Hydrocortisone</td>
</tr>
<tr>
<td>Methylprednisolone</td>
</tr>
<tr>
<td>Prednisolone / Prednisone</td>
</tr>
</tbody>
</table>
Reference


> Yates HL, Newell SJ. Minidex: very low dose dexamethasone (0.05 mg/kg/day) in chronic lung disease. Archives of Disease in Childhood-Fetal and Neonatal Edition. 2011 May 1;96(3):F190-4.

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: Health.NeoMed@sa.gov.au
Endorsed by: SA Safety and Quality Strategic Governance Committee
Next review due: 05/07/2023
ISBN number: 978-1-74243-958-7
PDS reference: CG023
Policy history:

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>5/7/18</td>
<td>V4</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Formally reviewed in line with 5 year scheduled timeline for review.</td>
</tr>
<tr>
<td>12/8/14</td>
<td>V3</td>
<td>SA Maternal &amp; Neonatal Community of Practice</td>
<td>Minor review</td>
</tr>
<tr>
<td>17/6/14</td>
<td>V2</td>
<td>SA Maternal &amp; Neonatal Community of Practice</td>
<td>Formally reviewed in line with 3 year scheduled timeline for review.</td>
</tr>
<tr>
<td>1/11/12</td>
<td>V1</td>
<td>SA Maternal &amp; Neonatal Community of Practice</td>
<td>Original SA Maternal &amp; Neonatal Community of Practice approved version.</td>
</tr>
</tbody>
</table>